OncoMatch/Clinical Trials/NCT06741722
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Is NCT06741722 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF for aml.
Treatment: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF — The DCMG regimen includes decitabine or azacitidine (hypomethylating agents), mitoxantrone liposome, cytarabine, and granulocyte colony-stimulating factor (G-CSF), comprising four medications. This project initiates a prospective and exploratory clinical study on the DCMG chemotherapy regimen for the treatment of relapsed/refractory AML (Acute Myeloid Leukemia). The study aims to evaluate the efficacy and safety of the DCMG combination chemotherapy regimen in treating relapsed/refractory AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anthracycline (mitoxantrone, mitoxantrone hydrochloride liposome injection)
Previously received mitoxantrone or mitoxantrone hydrochloride liposome injection
Cannot have received: anthracycline (doxorubicin, daunorubicin, idarubicin)
Exception: total cumulative dose of doxorubicin > 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin)
Previously received doxorubicin or other anthracyclines, with a total cumulative dose of doxorubicin > 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin)
Cannot have received: major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment
Underwent any major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment within 2 weeks before the first administration of the study drug
Lab requirements
Kidney function
serum creatinine ≤ 1.5 times the upper limit of normal
Liver function
Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range
Cardiac function
Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%
Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range, serum creatinine ≤ 1.5 times the upper limit of normal; Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06741722 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anthracycline, anthracycline, major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages